1177 — Sino Biopharmaceutical Balance Sheet
0.000.00%
- HK$122.39bn
- HK$127.39bn
- CNY28.87bn
- 92
- 29
- 93
- 86
Annual balance sheet for Sino Biopharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 16,432 | 15,794 | 16,922 | 14,118 | 14,818 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4,076 | 5,537 | 6,219 | 6,199 | 6,800 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 22,794 | 23,503 | 25,935 | 23,806 | 24,685 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 8,392 | 8,516 | 9,251 | 9,912 | 10,288 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 47,210 | 60,543 | 64,064 | 63,605 | 65,408 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 10,944 | 15,345 | 20,151 | 22,607 | 19,556 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 30,463 | 30,252 | 34,317 | 33,130 | 33,447 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 16,747 | 30,291 | 29,747 | 30,474 | 31,961 |
| Total Liabilities & Shareholders' Equity | 47,210 | 60,543 | 64,064 | 63,605 | 65,408 |
| Total Common Shares Outstanding |